Clinical Trials Network: Southwest Node

临床试验网络：西南节点

• 批准号: 8525364
• 负责人: Michael Parks Bogenschutz
• 金额: $ 109.73万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8525364
• 关键词: Accident and Emergency department; Adolescent; Alcoholism; American; American Indians; Area; Award; Behavior Therapy; Budgets; Buprenorphine; Clinical; Clinical Sciences; Clinical Trials; Clinical Trials Network; Collaborations; Communication; Counseling; Data; Dental; Development; Drug Addiction; Drug abuse; Drug usage; Educational workshop; Evaluation; Evidence based practice; Family; Funding; Grant; HIV/STD; Hispanics; Human Resources; Human immunodeficiency virus test; Individual; Intervention; Lead; Leadership; Life; Link; Location; Medical; Methamphetamine; Methods; Minority; Mission; Naloxone; National Institute of Drug Abuse; Native Americans; New Mexico; Occupations; Opiate Addiction; Opioid; Outcome; Outpatients; Participant; Patient Education; Pharmaceutical Preparations; Pharmacotherapy; Population; Principal Investigator; Procedures; Protocols documentation; Psychiatric therapeutic procedure; Recording of previous events; Recruitment Activity; Rehabilitation therapy; Research; Research Activity; Research Infrastructure; Research Personnel; Running; Science; Services; Site; Structure; Substance Addiction; Substance abuse problem; Surveys; Training; Treatment outcome; Underserved Population; United States; Universities; Work; addiction; cost; experience; follow-up; improved; innovation; meetings; member; men' s group; methadone maintenance; motivational enhancement therapy; multi-site trial; pregnant; programs; protocol development; public health relevance; quality assurance; rural area; safer sex; screening; skills; substance abuse treatment; treatment program; urban area; young adult

DESCRIPTION (provided by applicant): Since joining the NIDA Clinical Trials Network in 2002, the Southwest Node has made a substantial and singular contribution to the research activities of the CTN. The Southwest Node has successfully completed six multi-site trials, as well two studies focusing on Native Americans, two survey studies, and several ancillary and platform Studies. We are currently serving as Lead Node for CTN 0047, Screening, Motivational Assessment, and Referral for Treatment in Emergency Departments (SMART-ED). Beyond participation in protocols, the Node has been highly productive in the areas of protocol development, training, committee work, and dissemination. The Node has made an outstanding contribution to advancing the clinical science of addictions treatment in minority and other underserved populations. Of the multi-site trial participants recruited at the Southwest Node, 71% were Hispanic and 7% were Native American, not counting 427 participants thus far in the two Native American protocols. The Node has managed grant funds prudently and efficiently, requesting and spending only what is necessary to achieve our scientific objectives. For the renewal period, the Southwest Node will consist of its RRTC, the University of New Mexico Center on Alcoholism, Substance Abuse, and Addictions (CASAA), and affiliated investigators at the University of New Mexico; 5 primary CTPs, all of which have already collaborated extensively with Node investigators; and 6 secondary CTPs representing a wide range of medical, dental, and psychiatric treatment settings. Strengths of the Southwest Node include: 1) a well-established track record of clinical trials with both behavioral treatments and pharmacotherapies; 2) longstanding experience in the development and evaluation of innovative treatments for addictions; 3) extensive experience with minority and other underserved populations, and demonstrated ability to recruit them; 4) expertise in research on dissemination and training; and 5) geographic representation of the American Southwest. Our agenda for the renewal period will build on our strengths, with four proposed foci of research leadership: 1) implementing addiction treatment in medical settings; 2) optimizing addiction treatment for minority populations; 3) using the family to enhance treatment outcome; and 4) pharmacologic treatment of opioid dependence.

描述（由申请人提供）：自2002年加入NIDA临床试验网络以来，西南节点为CTN的研究活动做出了巨大而独特的贡献。西南节点已经成功完成了6项多站点试验，2项针对美国原住民的研究，2项调查研究，以及几项辅助和平台研究。我们目前是CTN 0047，筛查，动机评估和转诊治疗急诊科（SMART-ED）的牵头节点。除了参与协议之外，Node在协议开发、培训、委员会工作和传播方面也非常富有成效。该节点为促进少数民族和其他服务不足人群的成瘾治疗的临床科学做出了杰出贡献。在西南节点招募的多地点试验参与者中，71%是西班牙裔，7%是美洲原住民，不包括迄今为止两项美洲原住民协议中的427名参与者。Node谨慎而有效地管理赠款资金，只要求和花费实现我们科学目标所必需的资金。在续期期间，西南节点将由其RRTC、新墨西哥大学酒精中毒、药物滥用和成瘾中心（CASAA）和新墨西哥大学的附属调查人员组成；5个主要ctp，它们都已经与Node调查人员进行了广泛合作；以及6个二级ctp，代表广泛的医疗、牙科和精神病学治疗环境。西南淋巴结的优势包括：1)在行为治疗和药物治疗方面有着良好的临床试验记录；2)在开发和评估创新成瘾治疗方面的长期经验；3)与少数民族和其他服务不足的人群有广泛的经验，并证明有能力招募他们；4)传播和培训研究方面的专门知识；5)美国西南部的地理代表性。我们的续期议程将以我们的优势为基础，提出四个研究领导重点：1)在医疗环境中实施成瘾治疗；2)优化少数群体成瘾治疗；3)利用家庭提高治疗效果；4)阿片类药物依赖的药物治疗。